L-Asparaginase

Phase 3Protein / enzyme

L-Asparaginase is one of 115 small molecule programs targeting Adult Acute Lymphoblastic Leukemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Acute Leukemia of Ambiguous LineageActive, not recruiting

Adult Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Acute Leukemia of Ambiguous LineagePhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

L-Asparaginase

EERYtech Pharma

Phase 3

5 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Tafasitamab

Incyte

Preclinical

7 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT04440267

Q1 2030

Phase 2Recruiting

Acute Lymphoblastic Leukemia

NCT06336395

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia9 trials

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT02036489·107 enrolled

Show 6 more trials

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Completed·CChildren's Oncology Group·Phase 1/2·NCT00098839·134 enrolled

GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia

Completed·EERYtech Pharma·Phase 2/3·NCT01518517·85 enrolled

LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00526409·40 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 2·NCT00131053·120 enrolled

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

Lymphoma5 trials

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Unknown status·SSamsung Medical Center·Phase 2·NCT02544425·27 enrolled

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

Completed·SSt. Jude Children's Research Hospital·N/A·NCT00187122·42 enrolled

L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma

Completed·FFudan University·Phase 2·NCT00854425·40 enrolled

Show 2 more trials

Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

Unknown status·TThe University of Hong Kong·Phase 4·NCT03071822·50 enrolled

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Unknown status·TThe University of Hong Kong·Phase 3·NCT03623087·68 enrolled

Adult Acute Lymphoblastic Leukemia2 trials

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Unknown status·JJapan Adult Leukemia Study Group·Phase 3·NCT00131027·240 enrolled

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Completed·RRuijin Hospital·Phase 4·NCT01358253·100 enrolled

Treatment1 trial

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Leukemia1 trial

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT00176462·60 enrolled

1 more indication

Acute Leukemia of Ambiguous Lineage1 trial

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for L-Asparaginase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-Asparaginase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-Asparaginase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ERYtech Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: EERYtech Pharma

L-Asparaginase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2030

Trials by Indication[1]

Acute Lymphoblastic Leukemia9 trials

Lymphoma5 trials

Adult Acute Lymphoblastic Leukemia2 trials

Treatment1 trial

Leukemia1 trial

Acute Leukemia of Ambiguous Lineage1 trial

References

Drug Info

Quick Facts

Related News